Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management
Review published in Critical care (London, England) (2026)
Abstract
BACKGROUND: Regional citrate anticoagulation (RCA) is recommended by guidelines over systemic heparinization for continuous renal replacement therapy (CRRT). However, its use in patients with impaired citrate metabolism poses specific challenges and standardized guidance for managing RCA-related metabolic complications remains lacking. METHODS: A modified Delphi study was conducted according to a predefined protocol and reported in adherence with the CREDES (Conducting and REporting of DElphi Studies) checklist. The international expert panel comprised 29 clinicians and researchers from Europe, United States and Canada, with recognized expertise in RCA for CRRT in critically ill patients. Three iterative survey rounds were conducted to obtain agreement with proposed statements. RESULTS: Twenty-three experts completed all Delphi rounds, achieving consensus on twenty-two statements. RCA was considered feasible in patients with liver dysfunction, severe shock, or hyperlactatemia, with close monitoring and citrate dosing adjustment. Citrate accumulation can be prevented and managed using a stepwise approach, focused on reducing citrate delivery and discontinuing RCA in cases of overt accumulation. Metabolic alkalosis and electrolyte disturbances were identified as relevant but manageable complications, underscoring the need for individualizing CRRT settings. CONCLUSION: These consensus statements support the use of RCA during CRRT in critically ill patients with impaired citrate metabolism and provide practical guidance for monitoring and management of metabolic complications. However they reflect expert opinion, especially for questions with limited data and low-level evidence.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Regional citrate anticoagulation (RCA) is recommended by guidelines over systemic heparinization for continuous renal replacement therapy (CRRT). However, its use in patients with impaired citrate metabolism poses specific challenges and standardized guidance for managing RCA-related metabolic complications remains lacking.
Por qué esto importa para la hirudoterapia
Este consenso Delphi modificado convocó a un panel internacional (23 expertos que completaron todas las rondas) y alcanzó un acuerdo sobre 22 declaraciones acerca de la anticoagulación con citrato regional (RCA) para la terapia de reemplazo renal continuo, concluyendo que la RCA es viable incluso con un metabolismo del citrato alterado, siempre que se realice un monitoreo estrecho y un ajuste de la dosis, y ofreciendo orientación práctica sobre la acumulación de citrato y la alcalosis metabólica. La relevancia para la ASH es tangencial: el citrato es un anticoagulante de circuito extracorpóreo con un mecanismo totalmente ajeno al secretoma de las sanguijuelas, por lo que este documento es útil únicamente como recordatorio de que la "anticoagulación" abarca muchos mecanismos distintos y que los agentes derivados de Hirudo medicinalis/verbana abordan un nicho diferente (local, dirigido a la antitrombina/factores). Advertencia honesta: se trata de un consenso de opinión de expertos, no de datos experimentales, reconociendo explícitamente un nivel de evidencia bajo para varias declaraciones; no tiene conexión con las sanguijuelas ni con la hirudoterapia y debe citarse únicamente para delinear, y no para respaldar, la narrativa del secretoma de las sanguijuelas.
Citación
Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management.
Jacobs R et al. · Critical care (London, England), 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026